Sector consensus Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
21:32:16 18/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 53.75 USD | +3.27% |
|
+3.44% | +22.27% |
| 08-10 | Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date | MT |
| 08-10 | Novo Nordisk works to address FDA's findings at Indiana plant | FW |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 60.38 | +15.99% | 16 | ||||||
| 182.53 | +9.37% | 18 | ||||||
| 1,036.98 | +4.68% | 14 | ||||||
| 200.05 | +55.9% | 22 | ||||||
| 40.85 | +2.95% | 23 | ||||||
| 104.26 | +31.58% | 20 | ||||||
| 1,312.17 | -6.94% | 8 | ||||||
| 2,410.59 | +14.57% | 15 | ||||||
| 573.12 | +9.69% | 18 | ||||||
| 52.94 | +1.18% | 16 | ||||||
| 110.18 | +24.22% | 11 | ||||||
| 678.06 | +29.19% | 16 | ||||||
| 144.2 | +85.34% | 21 | ||||||
| 20.99 | +122.66% | 13 | ||||||
| 109.9 | +44.85% | 20 | ||||||
| 124.71 | +19.23% | 14 | ||||||
| 99.56 | +43.17% | 16 | ||||||
| 85.5 | +0.88% | 10 | ||||||
| 109 | +81% | 9 | ||||||
| - | - | - | - | - | ||||
| Average | 392.42 | +31.03% | 16 | ||||||
| Weighted average by Cap. | 489.93 | +22.25% | 16 |
- Stock Market
- Stocks
- SRRK Stock
- Sector Scholar Rock Holding Corporation
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
